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SAME-DAY VS. NEXT-DAY RECONSTRUCTION FOLLOWING MOHS 
MICROGRAPHIC SURGERY: A COMPARATIVE STUDY 
 
LOUIS P. ZINGAS 
ABSTRACT 
Background: Skin cancer is the most common malignant neoplasm, with more than 5.4 
million cases diagnosed annually in the United States. Treatment varies based on the type 
of neoplasm, its location, as well as primary vs. recurrent lesions. Nonetheless, surgical 
treatment remains the gold standard. Mohs micrographic surgery (MMS) is a commonly 
used surgical technique in the excision of such neoplasms. The technique of MMS allows 
for the precise removal of skin cancers while offering the highest cure rates with maximal 
preservation of surrounding tissue. Repairs of MMS defects are often done the same day if 
performed by the resecting Mohs surgeon. However, for more complicated reconstructive 
procedures, repairs are often performed by a separate reconstructive surgeon. When this 
occurs, MMS repairs may be delayed and performed on a different day due to a variety of 
factors such as surgical scheduling conflicts and patient tolerance. Researchers are urgently 
trying to explore the implications and postoperative complications of delayed MMS as 
compared to same day MMS.  
Objective: This study compares same-day vs. next day eyelid reconstruction following 
MMS with attention to postoperative complications. Our aim is to investigate whether or 
not a delay in closure is associated with an increase in postoperative complications.  
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Methods: We performed a retrospective chart review of patients who underwent eyelid 
reconstruction following MMS from January 2008 to December 2018, by a single private 
practice oculoplastic surgeon. The timing of each patient’s reconstruction along with age, 
sex, comorbidities, such as diabetes, current smoking status, previous radiation therapy, 
anticoagulation treatment, and occurrence of postoperative complications were recorded. 
The specific location of the defect was recorded as well. The timing of reconstruction was 
classified as same-day or next-day reconstruction. No reconstructions took place more than 
48 hours after tumor excision. The complications included in our analysis were: hematoma, 
wound infection, flap necrosis, dehiscence, and ectropion. Statistical significance was 
determined by Pearson’s chi-squared analysis. 
Results: A total of 485 procedures were performed on 390 patients. 334 (69%) of those 
procedures were same-day reconstructions, while 151 (31%) of those procedures were 
next-day reconstructions. 19 (5.7%) of the 334 same-day reconstructions and 9 (5.9%) of 
the 151 next-day reconstructions were associated with complications (p=0.905). Therefore, 
a total of 28 (5.8%) procedures were associated with complications. More women (54%) 
than men (46%) underwent reconstruction. Multivariate logistic regression showed that 
males had a 1.274-fold higher risk of developing complication post reconstruction. Current 
smokers had a 1.054-fold higher risk of developing complications post reconstruction.   
Conclusions: There is no statistically significant difference in the postoperative 
complication rate when comparing same-day vs. next-day eyelid reconstruction following 
Mohs micrographic surgery.  
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Non-Melanoma Skin Cancer in the United States 
Skin cancer is the most common malignant neoplasm, with more than 5.4 million cases 
diagnosed annually in the United States (American Cancer Society). Approximately 40% 
to 50% of Americans who live to age 65 years and beyond will have skin cancer at least 
once in their lifetime (Batra and Kelley 2002). Skin pigmentation has the most 
consequences on susceptibility to skin cancer (Scherer and Kumar 2010). Although it has 
been established that non-melanoma skin cancer is the most common type of skin cancer 
affecting white-skinned individuals, limited data are available for other skin types (Lomas, 
Leonardi-Bee et al. 2012). 
More specifically basal and squamous cell skin cancers are the most common types 
of skin cancer, where basal cell carcinoma occurs in 8 out of 10 skin cancers (American 
Cancer Society). They start in the top layer of the skin – the epidermis – and exposure to 
sunlight is often the most common cause (American Cancer Society). The epidermis is 
separated by the other skin layers via a barrier, namely the basal membrane. When 
neoplasms become more invasive they penetrate through this barrier and move into the 
deeper layers. The number of skin cancers has been increasing for many years, partly due 
to better skin cancer detection, people being more exposed to sun, as well as the baby 
boomer effect leading to people living longer (American Cancer Society). Although 5.4 
million cases annually present with skin cancer, mortality is limited to about 2000 people 
per year in the U.S. (American Cancer Society). Since non-melanoma skin cancer is 
generally encountered in the elderly population, Medicare is the primary payer for the 
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treatment of non-melanoma skin cancer. The estimated annual cost exceeds $526 million 
for the Medicare population and $650 million for the entire U.S. population (Mudigonda, 
Pearce et al. 2010). 
 
Treatment Modalities for Non-Melanoma Skin Cancer 
Treatment varies based on the type of neoplasm, its location, its histological pattern, as 
well as primary vs. recurrent lesions. Treatment modalities include Mohs micrographic 
surgery (MMS), traditional surgical excision, radiation therapy, electrodessication and 
curettage, cryosurgery, photodynamic therapy, and topical chemotherapeutic agents 
(Tierney and Hanke 2009). Surgery is the most frequent approach used to treat skin 
neoplasms. The gold standard for treatment is Mohs micrographic surgery (MMS), but the 
time consuming nature and cost of the procedure lead to MMS being indicated only in 
patients with aggressive tumors or those where disfigurement or functional impairment is 
a risk (Neville, Welch et al. 2007). Radiation therapy is effective, however, the side effects 
have limited its use to only patient who are not surgical candidates. Newer noninvasive 
treatment options include topical chemotherapeutics, biological-immune-response 
modifiers, retinoids, and photodynamic therapy, which are used mainly in patients with 
superficial tumors. Only photodynamic therapy and topical imiquimod have become 
established treatments for specific subtypes of basal-cell carcinoma, and the search for 
more effective and tissue-salvaging therapies continues (Madan, Lear et al. 2010). 
The high cost of treatment of skin cancer makes cost-effective treatment of skin 
cancer critical. Rogers et al., show that electrodessication and curettage (EDC) is the least 
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expensive treatment option at all tumor sizes they examined, at approximately 64% lower 
costs than MMS, and 55% lower than office-based excision (Rogers and Coldiron 2009). 
Treatment with topical chemotherapeutic agents, such as imiquimod, costs about the same 
amount as office-based excision, however, it is more expensive than excision at small 
lesion sizes (Rogers and Coldiron 2009). MMS is approximately 25% more expensive than 
office-based excision with small differences seen as the lesion size increases (Rogers and 
Coldiron 2009). Cryogenics and radiation therapy are substantially more expensive than 
office-based excision.  
Although EDC is the least costly option, certain disadvantages restrict its use to 
only superficial skin neoplasms. Therefore, it is difficult to identify tumors that could be 
treated with EDC without a complete histologic examination (Rogers and Coldiron 2009). 
Furthermore, recurrence of skin cancer after treatment with EDC is very frequent with 
significant subclinical extension, and is thus associated with inferior cosmetic outcome 
(Rogers and Coldiron 2009). Treatment with topical chemotherapeutic agents such as 
imiquimod has been deemed a relatively inexpensive nonsurgical treatment for non-
melanoma skin cancers (Warshauer and Warshauer 2008). However, there is a higher 
recurrence rate, as well as there are not enough studies to establish the safety and efficacy 
of imiquimod in non-superficial tumors (Rogers and Coldiron 2009). Furthermore, 
imiquimod has a slow course of action, which is suboptimal for the treatment of rapidly 
growing tumors (Rogers and Coldiron 2009). Radiation treatment is very expensive and 
requires multiple office visit; and although initially radiation has favorable cosmetic 
effects, it has been shown that patients appearance progressively deteriorates (Rupprecht, 
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Lippold et al. 2007, Rogers and Coldiron 2009). Finally, a substantial amount of patient 
experience ulceration post radiation, effectively thus requiring surgical intervention for the 
ulceration (Hernandez-Machin, Borrego et al. 2007). 
Studies examining the rates of positive surgical margins and recurrence rates for 
traditional surgical excision of non-melanoma skin cancer have yielded varied results. A 
positive surgical margin refers to cancer cells being present at the edges of the tissue, which 
effectively suggests that the whole tumor was not removed. Traditional surgical excision 
with permanent section margin control reveals rates of initial surgical margin involvement 
by non-melanoma skin cancer from 6.3% to 25.4% (Sussman and Liggins 1996, Dieu and 
Macleod 2002, Hussain and Earley 2003, Farhi, Dupin et al. 2007, Griffiths, Suvarna et al. 
2007). Evaluations of non-melanoma skin cancer recurrence rates after traditional surgical 
excision with permanent section margins have rates of 2% to 14% at 5 years post-surgery 
(Silverman, Kopf et al. 1992, Nagore, Grau et al. 2003, Walker and Hill 2006). Traditional 
surgical excision with frozen section margin control cites initial positive margins of 9% to 
21% (Bentkover, Grande et al. 2002) and recurrence rates of 2.1% to 10% (Bentkover, 
Grande et al. 2002). The rates of initially positive margins and recurrence of 11% and 10% 
for excision with permanent sections and of 21% and 10% for excision with frozen sections 
(Cook and Zitelli 1998). 
 
Defining Mohs Micrographic Surgery 
As defined by the American Medical Association Current Procedural Terminology, MMS 
is a technique for the removal of complex or ill-defined skin cancer with histologic 
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examination of 100% of the surgical margins. It is a combination of surgical excision and 
surgical pathology that requires a single physician to act in 2 integrated but separate and 
distinct capacities: surgeon and pathologist. If either of these responsibilities is delegated 
to another physician who reports the services separately, these codes should not be 
reported. The Mohs surgeon removes the tumor tissue and maps and divides the tumor 
specimen into pieces, and each piece is embedded into an individual tissue block for 
histopathologic examination. Thus, a tissue block in MMS is defined as an individual tissue 
piece embedded in a mounting medium for sectioning (American Medical Association). 
 
How is MMS Done? 
Mohs micrographic surgery was first developed in the 1930s by Dr. Frederic Mohs at the 
University of Wisconsin, and has since advanced into a precise and effective surgical 
technique used as a mainstream treatment for a variety of skin cancers (American College 
of Mohs Surgeons). The goal of Mohs surgical excision includes the removal of the visible 
parts of the tumor as well as a margin on normal looking tissue around the tumor to remove 
all clinically invisible tumor roots that extend into the body (Narayanan, Hadid et al. 2014). 
Mohs surgery begins with a surgeon’s thorough examination of the visible tumor and a 
plan as to which specific tissue will be surgically excised to start. In MMS, the tumor is 
removed by curettage or excision. Using a scalpel, the doctor removes the thinnest possible 
layer of visible cancerous tissue. The surgeon then color-codes each section of excised 
tissue and its corresponding location on the patient, allowing them to identify areas that 
may still contain cancerous tissue and other areas which may not. The physician then takes 
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the excised tissue to an on-site laboratory where a frozen histologic section is prepared. 
The patient must wait until the lab results come back. During this time, the tissue sections 
are examined under a microscopic in search of evidence of remaining cancer. The color 
marked on the tissue allows the physician to orientate each specific section to a section 
marked on the patient.  If a section on the tissue is found to have any remaining cancer 
cells, the patient has to undergo another resection from only the areas where cancerous 
tissue remains. In this way, MMS conserves the greatest amount of healthy tissue and offers 
the smallest possible scar. The surgical excisions continue until there is no longer evidence 
of cancer present. This process usually does not last more than a couple of hours (Cherpelis, 
Moore et al. 2009). A detailed step-by-step summary of MMS can be seen in Figure 1. 
 
Advantages and Disadvantages of MMS 
Mohs micrographic surgery (MMS) is the gold standard in the excision of neoplasms. 
MMS allows for the precise removal of skin cancers while offering the highest cure rates 
with maximal preservation of surrounding tissue (Patel, Liu et al. 2016). There is a 
misperception in the medical community that MMS is very expensive. However, MMS is 
the only procedure for the treatment of non-melanoma skin cancer that includes all surgery, 
pathology, and supply expenses in one cost being made to one provider (Rogers and 
Coldiron 2009). With the loss of the multiple surgery reduction exemption, the MMS cost 
has decreased by 9% to 25% (Rogers and Coldiron 2009). Importantly, MMS has a lower 
recurrence rate, and no second excision for initially positive margins, resulting in fewer 
patient visits (Rogers and Coldiron 2009). Therefore, MMS is a cost effective treatment 
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(Tierney and Hanke 2009). Studies on MMS have further found that MMS is as effective 
as local excision for early melanomas, and long-term patient satisfaction approximates 
95% (Condie, West et al. 2019). Finally, MMS is the most accurate in determining 
subclinical spread of skin cancer (Rowe, Carroll et al. 1989). 
 However, MMS is used to treat non-melanoma skin cancer of a size and anatomic 
location that is conducive to local anesthesia (Cumberland, Dana et al. 2009). The larger 
the tumor, the more time consuming the procedure will be, which might in turn increase 
the cost for the patient. General anesthesia is contraindicated due to the risks to the patient 
and the high cost. 
 
Who can get MMS? 
MMS has been increasingly used by physicians for many reasons. Significantly, a wide 
variety of patients are eligible for MMS based on guidelines from the American Academy 
of Dermatology, American College of Mohs Surgery, American Society for Dermatologic 
Surgery Association, and the American Society for Mohs Surgery (Ad Hoc Task, Connolly 
et al. 2012). 
While most MMS procedures are performed on relatively healthy patients, it is also 
appropriate for immunocompromised patients such as HIV patients, patients post organ 
transplant, patients with hematological malignancies, as well as individuals under 
pharmacologic immunosuppression. MMS is also used for individuals with basal cell 
nervous syndrome, xeroderma pigmentosum, or other syndromes at high risk for skin 
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cancer. MMS is also indicated in patients who have had prior radiated skin at the site of a 
cutaneous malignancy.  
The most common indications for MMS can be divided into six broad categories: 
tumors in critical anatomic sites where preservation of tissues is of paramount important; 
tumors with poorly delineated clinical borders of tumor arising from scar tissue; tumors 
with positive postoperative margins; large tumors; tumors with aggressive histology; 
recurrent basal and squamous cell carcinoma (Drake, Dinehart et al. 1995). 
Location of the neoplasm is critical in MMS, where MMS is most appropriate for 
functionally and cosmetically sensitive anatomic locations. More specifically, areas of the 
face including the eyelids, nose, lips and chin, ears, genitalia, hands, feet, nails, ankles and 
nipples, are highly appropriate candidates for MMS due to the need for tissue preservation 
(Mansouri, Bicknell et al. 2017). MMS is also useful for other sites, such as below the knee 
where patients may experience slower healing and higher rate of complications (Honaker, 
Bordeaux et al. 2016). 
Finally, consideration should be given to the growing demographic of elderly 
persons. Though cautions should be exercised in the elderly, the minimal incidence of 
complications associated with MMS under local anesthesia makes this population suitable 
for MMS (MacFarlane, Pustelny et al. 1997, Delaney, Shimizu et al. 2013). Miller et al., 
show that smoking status, defect size, full-thickness defects, interpolated flaps with 
cartilage grafting, and composite graft were associated with an increased risk of 
postoperative complications (Miller, David et al. 2018). Figure 2 below shows a 
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comprehensive summary of patient populations eligible for MMS. Furthermore, Figure 3 
summarizes the most common types of cancers treated via MMS.  
 
Adverse Events Associated with MMS 
MMS is safe with a very low rate of adverse events, and an undetectable mortality risk. A 
recent multi-center prospective inception cohort study of 21 private and 2 institutional US 
ambulatory referral centers for MMS showed that among 20,821 MMS procedures, there 
were 149 adverse events (0.72%), including 4 serious events (0.02%), and no deaths. 
Common adverse events reported were infections (61.1%), dehiscence and partial or full 
necrosis (20.1%), and bleeding and hematoma (15.4%). Patients on warfarin and 
clopidogrel have the highest risk of bleeding, although not severe enough to necessitate 
management outside the office setting (Syed, Adams et al. 2004, Bordeaux, Martires et al. 
2011). Use of some antiseptics and antibiotics and sterile gloves during MMS were 
associated with modest reduction of risk for adverse events (Alam, Ibrahim et al. 2013). 
Another study showed that in the absence of antibiotic prophylaxis, there were 11 surgical 
site infections among 1000 patients, three of which were complications of hematomas 
(Rogers, Desciak et al. 2010).  
 
 
Timing of Reconstruction After MMS 
Repairs of MMS defects are usually done the same day when performed by the resecting 
Mohs surgeon. However, if performed by a septate reconstructive surgeon MMS repairs 
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may be delayed and performed on a different day. Timing of reconstruction depends on the 
complexity and location of the MMS defect, patient anxiety and pain tolerance, and 
scheduling or availability of the reconstructive surgeon (Patel, Liu et al. 2016). There is a 
misconception that delayed closure leads to increased infection risk due to potential 
contamination of an exposed wound. However, delayed closure allows for more flexibility 
if additional time is needed to confirm clear tumor margins and is especially helpful when 
the resection and reconstruction are performed by separate surgeons (Patel, Liu et al. 2016). 
Commonly, delayed reconstruction takes place in patients with more complex or larger 
defects, since they are at risk for more complications (Patel, Liu et al. 2016).  
A recent study on the complication rates in delayed reconstruction of the head and 
neck after MMS identified a total 8.2% risk of complication (Patel, Liu et al. 2016), with 
atrial fibrillation and hematoma being the two immediate complications. Delayed 
complications included infection, vestibular stenosis, saddle nose deformity, septal 
perforation, and eyelid retraction. The overall infection rate was 2.4%. Patel et al., report 
that delay greater than two days presented with higher complication risk. Composite facial 
defects had a much higher complication rate, followed by interpolated flap with cartilage 
grafting, and delays greater than two days (Patel, Liu et al. 2016).  
Miller et al., report no association between timing of MMS reconstructive surgery 
and complications (Miller, David et al. 2018). Significantly, David et al., report that 
delaying grafting in patients who require full-thickness skin grafts and composite grafts is 




Reconstruction Post MMS 
A skin graft is a cutaneous free tissue transfer that is removed from the donor and 
transplanted to a recipient (Adams and Ramsey 2005). Full thickness skin grafts (FTSGs) 
consist of skin grafts obtained from the entire epidermis and dermis, whereas partial-
thickness skin grafts (PTSGs) include the entire epidermis and only partial parts of the 
dermis (Ramsey, Walker et al. 2020). FTSGs are easily harvested, and they are particularly 
well suited to defects on the nasal tip, dorsum, ala, and sidewall as well as on the eyelids 
and the ears (Trufant, Marzolf et al. 2016). FTSGs do not change the architecture of the 
recipient site and are manageable for both the patient and the surgeon (Ramsey, Walker et 
al. 2020). FTSGs are better than PTSGs in that there is less contraction on healing, better 
aesthetic result, and as a result there is thicker skin which is more resistant trauma (Ramsey, 
Walker et al. 2020). Nonetheless, FTSGs are associated with more graft failure, limit in 
the size of defects and choice of the donor site, and the time for healing of the donor site is 
much longer (Ramsey, Walker et al. 2020). 
 Adjacent tissue transfer graft (ATT) is another grafting technique that removes 
healthy tissue from an adjacent place to a scar. This achieves a much better aesthetic result 
since it comes from the same person, leads to smaller wounds, and maintains its blood 
supply. Significantly, ATT can be used for surgical defects that are too large, defects 
crossing cosmetic units, or those that are near free margins (Kaufman 2004). The 
myocutaneous pedicle flap (MPF) is another form of reconstruction, and refers to the use 
of the underlying muscle in the vicinity of the defect that is used as a flap. The pedicle flap 
has been proven to have great versatility in soft tissue and a large arc of rotation (Ong, Ji 
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et al. 2014). The extensive anastomotic network of the vessels in the head and neck allow 
for the successful use of these flaps in the reconstruction of large and deep defects (Tomas-
Velazquez and Redondo 2018). However, in majority of cases these flaps have been shown 
useful in the reconstruction of horizontal defects only (Tomas-Velazquez and Redondo 
2018). 
 Finally, the last reconstruction modality explained is the acellular dermal matrix 
(ADM) implants. ADM is a soft connective tissue graft generated by decellularization, 
which leads to an intact cutaneous extracellular matrix (Bohac, Danisovic et al. 2018). 
ADM is used for reconstructing nasal soft tissue and skeletal support, tympanic membrane, 
periorbital soft tissue, extraoral and intraoral defects, oropharyngeal defects, dura mater, 
and soft-tissue deficits from parotidectomy (Shridharani and Tufaro 2012). ADM is also 
useful in the prevention of Frey syndrome following parotidectomy and surgical treatment 
of facial paralysis (Shridharani and Tufaro 2012). ADM provides a very cosmetically 
appealing result, with minimal rejection potential due to its decreased antigenicity (Foley, 






This study compares same-day vs. next day eyelid reconstruction following MMS with 
attention to postoperative complications. Our aim is to investigate whether or not a delay 
in closure is associated with an increase in postoperative complications. We performed a 
retrospective chart review of patients who underwent eyelid reconstruction following 
MMS from January 2008 to December 2018, by a single private practice oculoplastic 
surgeon. The timing of each patient’s reconstruction along with age, sex, comorbidities, 
such as diabetes, current smoking status, previous radiation therapy, anticoagulation 
treatment, and occurrence of postoperative complications were recorded. The specific 
location of the defect was recorded as well. The complications included in our analysis 
were: hematoma, wound infection, flap necrosis, dehiscence, and ectropion.  
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Figure 1: Step-by-step analysis of Mohs Micrographic Surgery. (Tolkachjov, Brodland et 
al. 2017) 
15 
Figure 2. Indications for Mohs Micrographic Surgery. Adapted from Mansouri et al. 
(2017)(Mansouri, Bicknell et al. 2017) – continued on the next page 
16 
Figure 2 continued. Indications for Mohs Micrographic Surgery. Adapted from Mansouri 
et al. (2017)(Mansouri, Bicknell et al. 2017) 
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Figure 3. Types of tumors treated with Mohs Microscopic Surgery. Adapted from 
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Study Design and Participants  
We performed a retrospective medical record review from January 2008 to December 2018 
at the single private practice of an ophthalmologist specializing in oculoplastic surgical 
procedures in Providence, Rhode Island. Participants in this study were patients who 
underwent MMS. All patients had a minimum of one week of follow-up after their 
reconstruction. All participants were over 18 years of age. Both patients with same-day and 
next-day reconstruction were used. Next-day reconstruction was defined as taking place 
anywhere between 18-32 hours after the MMS surgery. No patients were excluded because 
of inadequate follow-up or incomplete medical records. No patients were excluded based 
on the tumor’s margins. Patients were excluded if the reconstruction was done more than 
32 hours after the resection. Data is de-identified after their collection; however, the 
database has pictures of the patients, which by definition is an identifier. This study did not 
entail examination of photographs, since some of them were not included in the medical 
record. Post-MMS wound care was not standardized since two different surgeons 
performed the MMS and the reconstruction. 
 
Data Collection and Main Outcome Measures 
A data file was created using STATA version 15.1 (StataCorp LLC, College Station, TX) 
to collect patient demographics, comorbidity, perioperative and postoperative data. Patient 
characteristics included sex, age, current smoking history, history of diabetes mellitus, use 
of anticoagulant or antiplatelet therapies, such as warfarin and clopidogrel, and history of 
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radiotherapy to the head and neck. Perioperative data included date of MMS surgery, date 
of reconstructive surgery, type of reconstructive modality, defect location, and defect size. 
Defects involving more than one facial unit were labeled composite defects, and full-
thickness defects were characterized for defects of the lips, nose, eyelid, auricles. 
Reconstructive modalities include adjacent tissue transfer (ATT), myocutaneous pedicle 
flap (MPF), acellular dermal matrix (ADM) implants, full-thickness skin grafting (FTSG), 
and combined reconstruction. We did not discriminate on the type of cancer that was 
treated, and patients presented with basal and squamous cell carcinoma, melanoma, and 
other types of skin cancer, including Merkel cell carcinoma, dermatofibrosarcoma 
protuberans, atypical fibroxanthoma, and sebaceous carcinoma. Unusual tumors such as 
Merkel cell carcinoma, dermatofibrosarcoma protuberans, atypical fibroxanthoma, and 
sebaceous carcinoma where there were very few cases, we grouped them under “other”.  
 
Main Outcome Measures 
The primary outcome measures were immediate and delayed postoperative complications 
corresponding to reconstructive surgery on the same day as MMS and 18 to 32 hours after 
MMS. Aesthetic outcomes were not assessed in this study. Immediate complications are 
defined as occurring 24 hours post-surgery, while delayed complications occurred more 
than 24 hours post-surgery. Any immediate complication was recorded, including wound-
related or systemic issues. Delayed complications included hemorrhage, hematoma, 
infection, skin necrosis, wound dehiscence, and others, such as vestibular stenosis, saddle 
deformity, or septal perforation. Hemorrhage was defined as bleeding requiring 
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intervention. Hematoma was defined by clinical examination and incision or drainage 
confirming the diagnosis. Wound dehiscence was defined as any noted separation along 
the suture line. Necrosis was defined as any skin flap or graft loss. Partial necrosis was 
defined as necrosis that healed with wound care. Complete graft loss was defined clinically 
as greater than 90% loss of the graft. Infection was defined as presence of erythema, 
purulence, increased tenderness, and/or induration. Antibiotics were prescribed in cases of 
concern of infection, and they were not prescribed as prophylaxis. We did not perform 
wound cultures to confirm the presence of an infection. Dehiscence was defined as any 
separation at the suture line.  
 
Wound Management  
All patients underwent MMS using standard surgical techniques. The wounds were kept 
dressed until reconstruction was performed. In case of delayed reconstruction, the patients 
were provided with adequate dressing as well as instructions in case they needed to change 
the dressing on their own in the meantime. At the time of reconstruction, all wounds were 
examined and prepared with Betadine. Nonviable tissues were removed from the wound. 
If a full-thickness skin graft was planned, minimal debridement took place. The 
reconstructive surgeon was responsible for follow-up, initially one week after surgery with 






Statistical Analysis  
A pooled prevalence for different complications was calculated, accompanied by 95% 
confidence intervals. Subgroup analysis was conducted based on the gender, the location 
of the defect, comorbidities present, and age. Finally, a time trend analysis was performed 
to evaluate the time trend of the prevalence of complications when reconstruction was 
performed both on the same day as MMS and after 24 hours. A multivariable logistic 
regression model was then created including all variables with a P<0.5 on univariate 
analysis. All statistical analyses were performed using STATA, version 15.1 (StataCorp 






Patient Characteristics  
A total of 485 defects were performed on 390 patients. 211 (54%) of all patients were 
women with 267 (55.1%) defects, and 179 (46%) were men with 218 (44.9%) defects. 334 
(69%) of those procedures were same-day reconstructions, while 151 (31%) of those 
procedures were performed 18-32 hours after MMS. The median age for same-day 
reconstruction was 63.3 years of age with an age range between 27-92 years of age and a 
standard deviation of 14.4 years. The median age for next-day reconstruction was 56.9 
years of age, with a range of 22-82 years of age and a standard deviation of 13.8 years. The 
modalities performed were adjacent tissue transfer (ATT), myocutaneous pedicle flap 
(MPF), acellular dermal matrix (ADM) implants, and full-thickness skin grafting (FTSG). 
Of the patients included in the study, 85 (21.8%) were current smokers, 96 (24.6%) were 
on antiplatelet therapy, 75 had a diagnosis of diabetes (19.2%), and 12 had undergone 
previous radiation treatment (3.1%). Univariate analysis was used to compare the 
association between days until reconstruction, reconstruction modality, type of defect, use 
of anticoagulants, diagnosis of diabetes mellitus, and current smoker history. P-values 
showed that age (P=0.000), gender (P=0.000), current smoking history (P=0.003), 
diagnosis of diabetes mellitus (P=0.000), and prior radiation of the head and neck 
(P=0.007) were statistically significant among same- and next-day reconstruction. 
Diagnosis of anticoagulation was not statistically significant (P=0.827). Patient 




For same-day reconstruction, 253 defects (75.7%) were reconstructed using ATT, 44 
(13.2%) were reconstructed using MPF, 23 (6.9%) were reconstructed using ADM 
implants, and 14 (4.2%) were reconstructed using FTSG. for delayed reconstruction, 97 
(64.2%) were reconstructed using ATT, 35 (23.2%) were reconstructed using MPF, 10 
(6.6%) were reconstructed using ADM, and 9 (6.0%) were reconstructed using FTSG. In 
women, there were 187 (55.9%) ATT grafts, 47 (14.1%) MPF grafts, 23 (6.9%) ADM 
grafts, and 10 (3.0%) FTSG grafts for same-day reconstructions. Among men there were 
136 (40.7%) ATT grafts, 49 (14.7%) MPF grafts, 21 (6.3%) ADM grafts, and 12 (3.6%) 
FTSG grafts for same-day reconstructions. In women, there were 66 (43.7%) ATT grafts, 
23 (15.2%) MPF grafts, 6 (4.0%) ADM grafts, and 5 (3.3%) FTSG grafts for next-day 
reconstructions. Among men there were 31 (20.5%) ATT grafts, 12 (7.9%) MPF grafts, 4 
(2.6%) ADM grafts, and 4 (2.6%) FTSG grafts for next-day reconstructions.  
 
Lesion and Cancer Characteristics 
Eye-related defects were the most common in our population, since this study was done in 
an ophthalmology practice. Among same-day reconstructions, eyelid defects made up 194 
(58.1%) defects, composite facial defects were 104 (31.1%), lip defects were 13 (3.9%), 
nasal defects were 23 (6.9%). Among next-day reconstruction, eyelid defects made up 86 
(57.0%) defects, composite facial defects were 47 (31.1%), lip defects were 5 (3.3%), and 
nose defects were 13 (8.6%). P-values showed that defect location (P=0.911) and size 
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(P=0.157) was not statistically significant for the timing of the reconstruction after MMS. 
Reconstruction modality was statistically significant for the timing of the reconstruction 
after MMS (P=0.029). Table 2 outlines the distribution of defect locations and 
reconstruction modalities for both same-day and delayed reconstruction.  
Basal cell carcinoma represented 347 (71.5%) of all 485 defects, 256 of the 347 
defects were reconstructed on the same day, and 91 of the 347 were reconstructed 24-32 
hours after the MMS procedure. The mean defect size was 2.5 cm2 (range: 0.1-45.4 cm2) 
for same-day reconstructions, and 3.2 cm2 (range: 0.1-63.7 cm2) for next-day 
reconstructions. P-value indicates that the type of cutaneous cancer is statistically 
significant among same- and next-say reconstruction (P=0.005). Table 3 shows the 
distribution of cutaneous cancers with basal cell carcinoma in both same day and next-day 
reconstructions.  
 
Complications Following Same-day and Next-day Reconstruction 
19 (5.7%) of the 334 same-day reconstructions and 9 (6.0%) of the 151 next-day 
reconstructions were associated with complications (P=0.905), for a total overall of 28 
complications (5.8). The P-value indicates that there is no statistically significant 
difference among immediate same-day complications and delayed next-day complications. 
Among immediate complications, there were 11 hematomas, 4 cases of atrial fibrillation, 
and 4 cases of ectropion. 9 of these defects were present in patients who had an eyelid 
defect, and 10 in patient who had composite defects. Among delayed complications, there 
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were 4 infections, and 5 cases of ectropion. Stratifying by defect size, only 1 postoperative 
infection was seen in patients with small defects, and 3 were associated with larger defects. 
Among next-day reconstructions, 7 complications presented among patients with eyelid 
defects, and 2 complications presented among patients with composite defects. Table 4 
outlines postoperative immediate and delayed complications.  
Ectropion was present in 4 of the 19 same-day complications, and 5 of the 9 next-
day complications. In total there were 9 ectropion cases. The age range was from 53 to 80 
years of age. There were only two women who developed ectropion, and in only three cases 
was ectropion developed from defects occurring on the right side of the patient. ATT was 
the most common reconstruction modality that led to ectropion, followed by ADM. The 
comorbidities of patients that were associated with the development of ectropion were 
fibromyalgia, hypertension, arthritis, and diabetes mellitus. All data on ectropion are 
summarized in Table 6.  
 
Multivariate Logistic Regression  
Multivariate logistic regression analysis was used to study the association between 
complications and timing of reconstruction. The analysis was adjusted for the parameters 
that were found statistically significant in the univariate analysis (sex, smoking, 
anticoagulation therapy, diabetes mellitus, reconstruction modality, and age). Patients with 
same-day reconstruction had a 0.862-fold lower risk of developing a complication (OR: 
0.862, 95% CI: 0.356, 2.151). Male patients had a 1.274-fold higher risk of developing a 
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complication (OR: 1.274, 95% CI: 0.544, 2.983).  Active smokers had a 1.054-fold higher 
risk of developing complications. Patients on anticoagulants had a 1.304-fold higher risk 
of developing complications. Patients with a diagnosis of diabetes mellitus had a 0.841-
fold risk of developing complications. Finally, when ATT was used as a procedure, the 
patient had a 0.531-fold lower risk of developing complications, whereas when MPF was 
used the patient had a 0.682-fold lower risk of developing complications. These risks of 
complications allow us to make predictions as to when reconstructions should and should 
not be delayed. When P-values were calculated, no statistical significance was found.  
 
Time Trend Analysis   
A meta-regression analysis was performed to evaluate the time trend of the prevalence of 
complications following MMS from January 2008 to December 2018. To model time 
trends, we defined as “index year” each year from 2008 to 2018. We then used the index 
year as a continuous variable in a meta-regression analysis. The analysis did not yield 
statistically significant results (meta-regression coef.: 0.004, p = 0.38), indicating that there 
is no significant increase or decrease in the number of complications post MMS surgery 





Table 1. Comparison of the patient demographic characteristics and comorbidities among 
patients who underwent 334 same-day and 151 next-day reconstructions  
Characteristic Value Chi-square P-value 







63.3 (27-92, ±14.4) 
 



















Defects stratified by 
gender 
Same-day reconstructions 
in females, No. (%) 
 
Same-day reconstructions 
in males, No. (%) 
 
Next-day reconstructions 
in females, No. (%) 
 
Next-day reconstructions 
















































































Prior head and neck 





















Table 1 Continued: Comparison of the patient demographic characteristics and 





reconstructions, No. (%) 
Next-day 















SD: standard deviation  





Table 2. Comparison of characteristics of defect location, size, and reconstruction 

































































stratified  by gender 
ATT in females, No. (%) 
ATT in males, No. (%) 
MPF in females, No. (%) 
MPF in males, No. (%) 
ADM in females, No. (%) 
ADM in males, No. (%) 
FTSG in females, No. (%) 






































Defect size, mean (range) 
cm2 
2.5 (0.1-45.4) 3.2 (0.1-63.7) 2.000 0.157 
ATT: adjacent tissue transfer, MPF: myocutaneous pedicle flap, ADM: acellular dermal 





Table 3. Distribution of cutaneous cancers among patients who underwent same-day and 
next-day reconstruction 









Basal cell carcinoma, 
No. (%) 









carcinoma, No. (%) 
47 (14.1) 37 (24.5) 
Melanoma, No. (%) 13 (3.9) 13 (8.6) 
Other, No. (%) 10 (3.0) 6 (4.0) 





Table 4. Types of postoperative immediate and delayed complications  






































Table 5. Multivariate Logistic Regression  
 
Variable Multivariate Model 
 OR (95% CI) P Value 
Timing of reconstruction 0.862 (0.356, 2.151) 0.751 
Sex: Male  1.274 (0.544, 2.983) 0.577 
Smoking 1.054 (0.314, 3.540) 0.933 





0.531 (0.143, 1.966) 




Age 1.018 (0.987, 1.050) 0.251 





Table 6. Characteristics of patients with eventual ectropion after reconstruction 
Age Gender  Reconstruction 
timing 
Procedure(s) Laterality Comorbidities 
53 F Same-day MPF, ADM R Fibromyalgia, 
Arthritis 
80 M Same-day ATT, ADM L Arthritis 
77 M Same-day ATT, MPF R DM 
76 M Same-day FTSG L Hypertension  
69 M Same-day ADM L DM, Hypertension 
76 F Next-day ATT R DM, Hypertension 
55 M Next-day FTSG L Arthritis 
77 M Next-day ATT, ADM L DM 
68 M Next-day ATT, MPF L DM 
F: Female; M: Male; ATT: adjacent tissue transfer; MPF: myocutaneous pedicle flap; 
ADM: acellular dermal matrix; FTSG: full-thickness skin grafting; R: Right; L: Left; 







Whereas complications after Mohs reconstructive surgery are not common, literature 
reports some types of complications in 1-19% of cases (Cook and Perone 2003, Patel, Liu 
et al. 2016). Patel et al., report that delaying reconstruction more than 2 days is associated 
with a higher rate of complications (Patel, Liu et al. 2016). This private practice sees a lot 
of MMS reconstructions referred from the community. Majority of the referrals regard eye-
related reconstructions, including composite defects that include the eye. Although, the 
office makes it a priority to reconstruct the defects as soon as possible because of patient 
wishes, conflicting schedules sometimes require that reconstructions are delayed. At our 
institution the maximum delay is 18-32 hours after MMS surgery. We have not identified 
an increased risk of complications with the next-day reconstructions. Significantly, 
sometimes reconstruction is delayed on purpose to allow for increased granulation in the 
tissue, in cases of larger defects, and in situations where more consultation is required with 
the patient. This practice has been based on clinical experience, thus, this is the first study 
of its sort taking place at our practice to identify the prevalence of complications during 
same-day and next-day reconstruction following MMS.  
The present study evaluated the association between timing of reconstruction and 
effects on complications. Patient characteristics were included in the analyses to identify 
potential confounding variables. In our study, the timing of the reconstructive surgery was 
not associated with an increased risk of postoperative complications. These findings are 
consistent with the results from Miller et al (Miller, David et al. 2018). Interestingly, in 
our study the rate of complications with next-day reconstruction was lower than the rate of 
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complications with same-day complications. Similarly, Robinson et al. report decreased 
rate of complications with delayed reconstruction (Robinson and Dillig 2002). 
Our study indicated an overall complications rate of 5.8%, which is a little lower 
than prior findings (Cook and Perone 2003, Patel, Liu et al. 2016, Miller, David et al. 
2018). This difference could be because this study took place in a small ophthalmology 
private practice in Rhode Island, while other studies took place at large academic medical 
centers, who get referred patients with more variable defect location and sizes. 
Furthermore, in most other studies majority of defects are nasal or composite defects which 
are surgically harder to repair and have been associated with a higher complication risk in 
previous studies (Sclafani, Sclafani et al. 2012). There were 19 complications with same-
day reconstructions, and 9 complications with next-day complications. Among same-day 
reconstructions, 9 defects were seen in patients with eyelid defects, and 10 defects were 
seen in patients with composite defects. Among next-day reconstructions, 7 defects were 
seen in patients with eyelid defects, and 2 defects were seen in patients with composite 
defects. It is difficult to compare this study to other studies, because of the retrospective 
nature, the different settings (private practice vs. large academic medical center), and the 
lack of uniform criteria for defining the complications that were considered in the analyses.  
Our univariate analysis indicated that age, gender, current smoking status, 
diagnosis of diabetes mellitus, and prior head and neck radiation were statistically 
significant when it came to the timing of reconstruction. Anticoagulation was not 
statistically significant. These variables were chosen because they have been reported in 
the literature to affect postoperative outcomes (David, Miller et al. 2019). Our multivariate 
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regression analysis showed that current smoking status, age, anticoagulation therapy, and 
male gender were associated with an increased risk of complications in patients. Male 
gender was associated with an increased risk of complication in other studies (Thibault and 
Bennett 1995). It is hypothesized that males have higher sebaceous gland density which 
leads to a higher complication risk. There are reports in the literature that have established 
an association between smoking and an increased risk of complications following 
reconstruction (Sclafani, Sclafani et al. 2012). Therefore, it might be advisable for 
reconstruction to be delayed in these patients.  
Defect size was not associated with increased risk of complications, however, we 
suspect this is because relatively small defects were present in this study, as a result of most 
defects being located on the eyelid. Furthermore, the  majority of complications both on 
same-day and next-day reconstruction were seen with composite defects, which has been 
documented in the literature (Teltzrow, Arens et al. 2011). Anticoagulation therapy, such 
as warfarin use, could predispose patients to higher risk of bleeding both during and after 
reconstruction. However, both our study and other studies have affirmed that 
anticoagulation therapy does not lead to higher complication rates (Kraft, Bellile et al. 
2015). Every patient is unique and should be evaluated individually, however, this research 
supports maintaining medically important anticoagulation treatment for relatively minor 
procedures. The 2017 cutaneous surgery guidelines (Kreicher and Bordeaux 2017) suggest 
that medically necessary anticoagulant and antiplatelet therapy be continued during 
cutaneous surgery.  
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Our study showed that diabetes mellitus was shown to have a decreased risk of 
complications following MMS reconstruction. However, we did not monitor whether the 
patients’ diabetes was controlled or uncontrolled, so it is hard to comment on the role of 
diabetes on the risk of complication post reconstruction. The significance of our 
multivariate analysis lies with the odds ratios and what they mean for patients’ health post 
during the procedure but also post-reconstruction. That is, smoking carries a 1.054-fold 
higher risk of leading to complications following reconstruction. This might provide an 
avenue for physicians to encourage smoke-cessation behaviors and programs that would 
both improve short term recovery outcomes in relation to the reconstruction, as well as 
long-term lifestyle and healthcare related consequences. Finally, regarding reconstruction 
modalities, the multivariate analysis indicates that ATT and MPF were associated with 
decreased risk of complications. This is important given the high incidence of ATT 
procedures in our practice, suggesting that when ATT and MPF are the modalities of choice 
by the provider and the patient, it might be advisable that the procedure happens on the 
same day as the MMS procedure. Robinson and Dillig (Robinson and Dillig 2002) have 
reported that when FTSG is used for reconstruction, delaying FTSG was associated with 
improved wound healing, aesthetic results and functional outcomes, which was later 
attributed to increased granulation of the tissue at the time of reconstruction. 
Future studies need to focus on establishing an optimal period for improved graft 
outcomes based on graft success, aesthetic outcomes and wound complications. It seems 
that granulation time is critical in maintaining a lower risk of complications, as well as 
improving the aesthetic outcomes. Thus, more studies are needed to assess wound beds 
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both at consultation and just before reconstruction in order to determine the potential need 
for more delayed reconstruction. Finally, since males are more predisposed to an increased 
risk of complications, and sebaceous gland density is hypothesized to play a role, more 
studies are needed to determine the role of sebaceous gland density on complication risk.    
Since this is an ophthalmology practice, and most of the defects were pertaining to 
the eyelid or an area composite with an eyelid, we took a special interest in ectropion 
(inverted eyelid) as a complication. The use of perioperative antibiotics, sterile technique, 
meticulous hemostasis, subcutaneous dissection and deep sutures to minimize wound 
tension should be considered for all Mohs reconstructions (Berens, Akkina et al. 2017). In 
general, reconstruction near the lower eyelid necessitates periosteal suspension sutures to 
minimize downward tension and lid retraction (Berens, Akkina et al. 2017). 
 
Strengths and Limitations 
 
This study included a relatively large sample size, which reduces potential bias that is 
introduced by the nature of this study as a retrospective cohort study. Furthermore, we 
included composite defects in our analysis which allows for a more rounded understanding 
of the role of wound location on the development of complications.  
This was a retrospective study relying on the completeness and accuracy of 
patients’ medical records, especially since these records were not used for this particular 
study. Since the data from the medical records were recorded a long time before the start 
of the study, there might be a lack of data on confounding variables. Importantly, the 
retrospective nature of this study makes it difficult to compare studies since different 
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providers define complications in different ways. In a retrospective study, it is difficult to 
control bias and confounders, since there is no randomization or blinding.  
The outcome we chose to measure here was the timing of reconstruction, and we 
chose to study same-day reconstruction and next-day reconstruction, where next-day was 
defined as 18-32 hours after when the MMS surgery took place. Since most other studies 
address the effects of a longer time period of delay in reconstruction, it is hard for us to 
compare our results with those of other studies.  
Furthermore, we did not assess for either patient anxiety or pain as a complication 
of the timing of reconstruction. However, this could be significant given the urgent nature 
of antibiotic resistance as well as the opioid epidemic. Significantly, this study did not try 
to assess aesthetic outcomes in relation to the timing of the reconstruction. Undesirable 
aesthetic outcomes may be another potential complication. This parameter could have been 
assessed using photographs of our patients from the available database. However, we did 
not have complete photographs for all patients, and therefore, we did not use photographs 







This study did not show a significant relationship between timing of reconstruction and 
risk of complications. Meaning that delaying surgery was not associated with an increased 
risk of post-operative complications. This study supports individualized evaluation of each 
patient when weighing the advantages and disadvantages of delayed reconstruction. It is 
possible that for larger defects, delayed reconstruction might be advised in order to allow 
for more extended granulation and thus better healing and aesthetic outcome. Delayed 
wound closure has the potential benefit of better patient counseling, as well as improved 
accommodation of physician scheduling issues. Our multivariate analysis showed that 
smoking, age and male sex were associated with an increased risk of complications. ATT 
and FTSG were the reconstruction modalities associated with decreased risk of 
complications. Additional studies are needed to study both the importance of granulation 
in improved aesthetics, as well as increased risk of complications in men. Finally, more 
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